It showed that gefitinib and SSD had a stronger anticancer impact on NSCLC cells, and that STAT3/Bcl-2 signaling pathway suppression was a molecular mechanism behind this mechanism, putting out a viable strategy for treating NSCLC patients who are EGFR-TKI resistant [50]. Here, BCL2 is linked to non-small cell lung carcinoma.